<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.0 20040830//EN" "journalpublishing.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="2.0" xml:lang="en" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Form Res</journal-id><journal-id journal-id-type="publisher-id">formative</journal-id><journal-id journal-id-type="index">27</journal-id><journal-title>JMIR Formative Research</journal-title><abbrev-journal-title>JMIR Form Res</abbrev-journal-title><issn pub-type="epub">2561-326X</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">v10i1e93531</article-id><article-id pub-id-type="doi">10.2196/93531</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Symptom-Specific Factors Associated With Chronic Constipation in Older Adults: Cross-Sectional Survey of Patient-Reported Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Takenaka</surname><given-names>Michinobu</given-names></name><degrees>PharmB</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Mitsuoka</surname><given-names>Toshinari</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sakurai</surname><given-names>Hidehiko</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><institution>Shirakaba Pharmacy Co. Ltd, Hokkaido University of Science</institution><addr-line>Sapporo</addr-line><addr-line>Hokkaido</addr-line><country>Japan</country></aff><aff id="aff2"><institution>Faculty of Pharmaceutical Sciences, Hokkaido University of Science</institution><addr-line>15-4-1, Maeda 7-jo, Teine-ku</addr-line><addr-line>Sapporo</addr-line><addr-line>Hokkaido</addr-line><country>Japan</country></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Law</surname><given-names>Stephanie</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name name-style="western"><surname>Zhang</surname><given-names>Xinghe</given-names></name></contrib></contrib-group><author-notes><corresp>Correspondence to Toshinari Mitsuoka, PhD, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 15-4-1, Maeda 7-jo, Teine-ku, Sapporo, Hokkaido, 006-8585, Japan, 81 11-676-8728, 81 11-676-8666; <email>mitsuoka-t@hus.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>10</day><month>7</month><year>2026</year></pub-date><volume>10</volume><elocation-id>e93531</elocation-id><history><date date-type="received"><day>14</day><month>02</month><year>2026</year></date><date date-type="rev-recd"><day>12</day><month>06</month><year>2026</year></date><date date-type="accepted"><day>12</day><month>06</month><year>2026</year></date></history><copyright-statement>&#x00A9; Michinobu Takenaka, Toshinari Mitsuoka, Hidehiko Sakurai. Originally published in JMIR Formative Research (<ext-link ext-link-type="uri" xlink:href="https://formative.jmir.org">https://formative.jmir.org</ext-link>), 10.7.2026. </copyright-statement><copyright-year>2026</copyright-year><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link ext-link-type="uri" xlink:href="https://formative.jmir.org">https://formative.jmir.org</ext-link>, as well as this copyright and license information must be included.</p></license><self-uri xlink:type="simple" xlink:href="https://formative.jmir.org/2026/1/e93531"/><abstract><sec><title>Background</title><p>In older adults with chronic constipation, symptoms of defecation difficulty often persist despite improvements in bowel movement frequency. However, constipation-related symptoms have rarely been examined as independent outcomes.</p></sec><sec><title>Objective</title><p>The objective of this study is to explore factors associated with constipation-related symptoms, less than 3 spontaneous bowel movements per week, straining during bowel movements, a sensation of incomplete evacuation, and a sensation of anorectal obstruction or blockage.</p></sec><sec sec-type="methods"><title>Methods</title><p>A cross-sectional web-based survey was conducted to collect patient-reported data. Constipation-related symptoms were defined according to the Rome IV criteria. Each symptom was treated as a binary variable in the analyses. Multivariable logistic regression analyses were used to examine associations between stool characteristics and medication, treatment processes, and lifestyle-related factors. Stool characteristics were classified using the Bristol Stool Form Scale, with hard stools defined as types 1 and 2.</p></sec><sec sec-type="results"><title>Results</title><p>We enrolled 546 participants and investigated the following constipation symptoms: less than 3 spontaneous bowel movements per week (n=226, 41.4%), straining (n=330, 60.4%), sensation of incomplete evacuation (n=344, 63.0%), and sensation of anorectal obstruction or blockage (n=242, 44.3%). Multivariable logistic regression analyses for these outcome variables showed that hard stool was consistently and independently associated with all constipation-related symptoms (odds ratio [OR] 1.86&#x2010;4.66). Symptom-specific associations that remained significant after false discovery rate adjustment included lower physical activity with less than 3 spontaneous bowel movements per week (OR 0.86, 95% CI 0.77&#x2010;0.96), stimulant laxative use with the sensation of incomplete evacuation (OR 2.01, 95% CI 1.22&#x2010;3.31), and lower adherence to the prescribed dosage with the sensation of anorectal obstruction or blockage (OR 0.87, 95% CI 0.78&#x2010;0.97). In contrast, the experience of adverse effects was associated with a higher probability of less than 3 spontaneous bowel movements per week and the sensation of anorectal obstruction or blockage.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In older adults with chronic constipation, different constipation-related symptoms showed distinct patterns of association, while hard stool consistency emerged as a common factor across symptoms. These exploratory findings may support symptom-oriented assessment and help inform individualized management approaches using electronically collected patient-reported outcomes.</p></sec></abstract><kwd-group><kwd>constipation</kwd><kwd>older adults</kwd><kwd>laxative therapy</kwd><kwd>patient-reported outcomes</kwd><kwd>gastroenterology</kwd><kwd>bowel</kwd><kwd>digestive</kwd></kwd-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Chronic constipation is a functional gastrointestinal disorder frequently observed in older adults. It is a heterogeneous syndrome characterized by multiple symptoms, including reduced bowel movement frequency, straining during defecation, a sensation of incomplete evacuation, and anal obstruction [<xref ref-type="bibr" rid="ref1">1</xref>]. In older adults, a combination of age-related decreases in intestinal motility, reduced physical activity, and polypharmacy contributes to the complexity of symptom presentation and treatment responses [<xref ref-type="bibr" rid="ref2">2</xref>].</p><p>Consequently, in older adults with chronic constipation, symptoms such as straining during defecation, the sensation of incomplete evacuation, and the sensation of anorectal obstruction or blockage may persist even when the frequency of bowel movements is sufficient [<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref>]. These symptoms are included in the Rome IV diagnostic criteria for chronic constipation [<xref ref-type="bibr" rid="ref5">5</xref>]. However, many prior studies have primarily evaluated the frequency of spontaneous bowel movements [<xref ref-type="bibr" rid="ref6">6</xref>] and the severity of constipation [<xref ref-type="bibr" rid="ref7">7</xref>] as primary outcomes. Although individualized management tailored to specific symptoms is increasingly important, evidence regarding factors associated with individual symptoms remains limited [<xref ref-type="bibr" rid="ref8">8</xref>].</p><p>In addition, stool consistency, particularly hard stools, has been shown to be a pathophysiological factor potentially involved in reduced stool frequency and in common defecation disorder symptoms, such as straining, the sensation of incomplete evacuation, and anal obstruction [<xref ref-type="bibr" rid="ref9">9</xref>].</p><p>Meanwhile, treatment process elements (eg, experience of adverse effects, adherence to prescribed dosages, and shared treatment goals) and lifestyle factors (eg, fluid intake and physical activity) have been suggested to be associated with symptoms, in addition to pharmacotherapy, in the management of chronic constipation [<xref ref-type="bibr" rid="ref10">10</xref>]. However, few studies have systematically integrated clinical characteristics, treatment processes, and lifestyle habits into a single analytical model to examine their symptom-specific associations within the same cohort.</p><p>Therefore, this study employed a cross-sectional design targeting adults aged 65 to 74 years with chronic constipation who were receiving treatment. We collected patient-reported data from a web-based survey and aimed to explore the relationship between individual constipation-related symptoms and clinically relevant factors under pharmacological treatment. This study was not designed to test any specific pre-existing hypotheses but was rather planned as an exploratory study to generate clinical hypotheses for future investigation by identifying factors associated with various symptoms in patients with chronic constipation. This approach may help characterize each symptom, thereby providing insights that could contribute to the development of more individualized management strategies through digital tools, beyond focusing solely on bowel movement frequency.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2-1"><title>Study Design and Participants</title><p>This cross-sectional study was based on an anonymous, self-administered, web-based questionnaire survey conducted in Japan in July 2024. After obtaining approval from the Institutional Review Board, participants were recruited through Macromill, Inc, a research panel company that maintains a nationwide panel of registered monitors, including a disease-specific panel of patients with chronic constipation. This study was conducted as a closed web-based survey, and members of the chronic constipation panel were invited through email using a consecutive convenience sampling method. The purpose and content of the study were explained on the survey screen, and only participants who provided consent were included in the survey. The participants were older adults aged 65 to 74 years who took constipation medications prescribed by medical institutions for at least 4 days per week, excluding those who used the medication on an as-needed basis. The reason for limiting the target age range from 65 to 74 years was to ensure the reliability of self-reported data in an online survey and to minimize the influence of severe cognitive decline and marked physical functional impairment, which are more common among adults aged 75 years and older.</p><p>Participants with restricted fluid intake, diet, or physical activity due to physician instructions were excluded because these medically prescribed restrictions might prevent actual behaviors from accurately reflecting usual lifestyle habits, thereby potentially confounding the assessment of lifestyle factors.</p></sec><sec id="s2-2"><title>Measurements</title><p>The constipation-related symptoms, stool consistency, treatment process factors, and lifestyle factors analyzed in this study are listed in <xref ref-type="table" rid="table1">Table 1</xref>. In this study, each variable was operationally defined based on the respondent&#x2019;s self-reported assessment of the corresponding questionnaire item. Details of the questionnaire items are provided in Table S1 in <xref ref-type="supplementary-material" rid="app1">Multimedia Appendix 1</xref>.</p><table-wrap id="t1" position="float"><label>Table 1.</label><caption><p>Variables and their definitions used in the study.</p></caption><table id="table1" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Category and variables</td><td align="left" valign="bottom">Definition or categorization</td></tr></thead><tbody><tr><td align="left" valign="top">Outcome variables</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Fewer than 3 spontaneous bowel movements per week</td><td align="left" valign="top">Presence of less than 3 spontaneous bowel movements per week (yes/no)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Straining during bowel movements</td><td align="left" valign="top">Presence of straining in &#x2265;1 out of 4 bowel movements (yes/no)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sensation of incomplete evacuation</td><td align="left" valign="top">Presence of sensation of incomplete evacuation (yes/no)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sensation of anorectal obstruction or blockage</td><td align="left" valign="top">Presence of sensation of anorectal obstruction or blockage (yes/no)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Manual maneuvers to facilitate defecation</td><td align="left" valign="top">Presence of manual maneuvers to facilitate defecation (yes/no)</td></tr><tr><td align="left" valign="top">Demographic factor</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Age (y)</td><td align="left" valign="top">65 to 74 years (continuous)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Sex</td><td align="left" valign="top">Male/female</td></tr><tr><td align="left" valign="top">Stool-related factor</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Hard stool</td><td align="left" valign="top">BSFS<sup><xref ref-type="table-fn" rid="table1fn1">a</xref></sup> type 1&#x2010;2 versus others</td></tr><tr><td align="left" valign="top">Medical factors</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Specialty of prescribing physician</td><td align="left" valign="top">Gastroenterology/coloproctology versus others</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Experience of adverse effects</td><td align="left" valign="top">Yes/no</td></tr><tr><td align="left" valign="top">Medication use</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Osmotic laxatives</td><td align="left" valign="top">Yes/no</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Stimulant laxatives</td><td align="left" valign="top">Yes/no</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Gastric acid&#x2013;suppressing agents</td><td align="left" valign="top">Yes/no</td></tr><tr><td align="left" valign="top">Treatment process factors</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Shared treatment goals</td><td align="left" valign="top">7-point scale (1=&#x201C;strongly disagree&#x201D; to 7=&#x201C;strongly agree&#x201D;)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Adherence to prescribed dosage</td><td align="left" valign="top">7-point scale (1=&#x201C;never&#x201D; to 7=&#x201C;always&#x201D;)</td></tr><tr><td align="left" valign="top">Lifestyle factors</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Probiotic intake</td><td align="left" valign="top" rowspan="4">7-point scale (1=&#x201C;absolutely not applicable&#x201D; to 7=&#x201C;absolutely applicable&#x201D;)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Physical activity</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Dietary fiber intake</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Daily fluid intake</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>BSFS: Bristol Stool Form Scale.</p></fn></table-wrap-foot></table-wrap><sec id="s2-2-1"><title>Outcome Variables</title><p>The following outcome variables were defined: less than 3 spontaneous bowel movements per week, straining during bowel movements, sensation of incomplete evacuation, sensation of anorectal obstruction or blockage, and the presence or absence of manual maneuvers to facilitate defecation (defined as one of the symptoms in the Rome IV criteria). Each constipation-related symptom was dichotomized as 1 (&#x201C;present&#x201D;) or 0 (&#x201C;absent&#x201D;). These symptoms were defined based on the symptom definitions of chronic constipation according to the Rome IV criteria [<xref ref-type="bibr" rid="ref11">11</xref>]. However, outcomes with a low number of events were excluded from the multivariable analysis because they might not meet the event count required for multivariable logistic regression analysis.</p></sec><sec id="s2-2-2"><title>Explanatory Variables</title><p>Sex was included as a basic attribute in this analysis. Sex was treated as a covariate because previous studies have reported that it can influence the pathophysiology and symptom profile of individuals with chronic constipation [<xref ref-type="bibr" rid="ref1">1</xref>].</p><p>Stool consistency was assessed using the Bristol Stool Form Scale (BSFS) and classified as hard stool (types 1&#x2010;2) or otherwise [<xref ref-type="bibr" rid="ref12">12</xref>]. Hard stools are a pathological factor that may cause multiple constipation symptoms. Therefore, in this study, they were included as an explanatory background factor, independent of symptom outcome variables, and were used to examine the factors associated with specific symptoms.</p><p>Medical-related factors were classified based on the prescribing department as gastroenterology, digestive medicine, proctology, or others. Additionally, adverse effects associated with constipation medications were operationally defined as self-reported experiences of symptoms (eg, severe diarrhea or abdominal pain) attributed to laxative use. Participants were asked whether they had experienced any such side effects using a yes/no response format. Responses were dichotomized as &#x201C;present&#x201D; when participants reported experiencing any of these symptoms, and &#x201C;absent&#x201D; otherwise. No further subtype definitions or severity grading criteria were applied to minimize respondent burden in this online survey of older adults. Medication usage status, specifically the use of osmotic laxatives (saline laxatives), stimulant laxatives, and gastric acid secretion inhibitors, was also assessed. The type of constipation medication used was classified based on multiple-choice and open-ended questions. Acid secretion inhibitors were included as background factors in the analysis because they have been suggested to affect the intestinal microbiota and stool characteristics, potentially correlating with constipation symptoms and defecation abnormalities [<xref ref-type="bibr" rid="ref13">13</xref>-<xref ref-type="bibr" rid="ref15">15</xref>].</p><p>The treatment process factors included shared treatment goals and adherence to the prescribed dosages. Specifically, these items were developed with reference to the Necessity-Concerns Framework [<xref ref-type="bibr" rid="ref8">8</xref>], an academic framework describing treatment behaviors and medication beliefs in patients with chronic conditions. These factors are treatment process elements potentially related to patients&#x2019; understanding of treatment and medication awareness and have been suggested to influence medication behavior and treatment continuity in long-term therapy [<xref ref-type="bibr" rid="ref16">16</xref>].</p><p>Shared treatment goals were assessed using the question, &#x201C;Do you feel you share treatment goals for constipation symptoms with your prescribing physician?&#x201D; Responses were recorded on a 7-point scale ranging from 1 (&#x201C;strongly disagree&#x201D;) to 7 (&#x201C;strongly agree&#x201D;).</p><p>Adherence to the prescribed dosage was assessed using the question, &#x201C;How often do you follow the prescribed dosage and frequency of your constipation medications or laxatives as instructed by your physician or pharmacist?&#x201D; Responses were recorded on a 7-point scale ranging from 1 (&#x201C;never&#x201D;) to 7 (&#x201C;always&#x201D;).</p><p>Lifestyle factors, including the consumption of lactic-acid bacterial products, exercise habits, dietary fiber intake, and daily fluid intake, were selected based on recommendations from international organizations (American Gastroenterological Association&#x2013;American College of Gastroenterology and World Gastroenterology Organization) and Japanese clinical practice guidelines for chronic constipation [<xref ref-type="bibr" rid="ref17">17</xref>-<xref ref-type="bibr" rid="ref19">19</xref>], as well as reviews on nonpharmacological interventions for managing chronic constipation [<xref ref-type="bibr" rid="ref20">20</xref>-<xref ref-type="bibr" rid="ref23">23</xref>]. The detailed operational definitions and questionnaire items used to assess lifestyle factors are shown in Table S1 in <xref ref-type="supplementary-material" rid="app1">Multimedia Appendix 1</xref>. Specifically, each factor was operationalized as the participant&#x2019;s self-reported degree of implementation of the corresponding constipation-related lifestyle behavior in daily life. Each item was assessed using a 7-point scale ranging from 1 (&#x201C;absolutely not applicable&#x201D;) to 7 (&#x201C;absolutely applicable&#x201D;).</p><p>Questionnaire items related to lifestyle factors, shared treatment goals, and adherence were subjected to a content validity review by an interdisciplinary expert panel consisting of 6 members (3 pharmacists, 1 general practitioner, 1 regulatory science specialist, and 1 medication adherence researcher). The panel evaluated the clarity, clinical relevance, and appropriateness of each item.</p><p>Given that the target population comprised adults aged 65 to 74 years and that the survey was administered online, a concise questionnaire design was adopted to minimize respondent burden and maintain response quality. Previous methodological research has suggested that single-item measures may be appropriate when the objective is to capture respondents&#x2019; overall subjective appraisal of clearly interpretable constructs in large-scale surveys [<xref ref-type="bibr" rid="ref24">24</xref>]. As this study focused on global perceptions rather than detailed multidimensional assessments of each construct, each variable was evaluated using a single-item scale.</p></sec></sec><sec id="s2-3"><title>Statistical Analysis</title><p>Descriptive statistics are presented as mean (SD) for continuous variables and as numbers and percentages for categorical variables. Multivariable logistic regression analyses were performed for each constipation-related symptom. All variables were entered simultaneously into the model using the forced-entry method. This approach was used to estimate the independent association of each factor with each symptom after adjustment for the other covariates. In the multivariable analysis, odds ratios (ORs) and 95% CIs were calculated. The overall performance of the multivariable logistic regression models was evaluated using the area under the receiver operating characteristic curve (AUC) and the Hosmer-Lemeshow goodness-of-fit test. To account for the increased risk of type I error associated with multiple exploratory outcome analyses, a multiplicity adjustment was applied. <italic>P</italic> values were corrected using the Benjamini-Hochberg method to control the false discovery rate (FDR). Given that this study is exploratory in nature, this approach was determined to be more appropriate than a stricter family-wise error correction, as it helps suppress false-positive findings while reducing the risk of overlooking potentially relevant factors. Statistical significance was defined as an adjusted <italic>P</italic> value of less than .05. IBM SPSS Statistics version 30.0 and R version 4.6 (R Foundation for Statistical Computing) were used for statistical analysis. However, outcomes with a low number of events were excluded from the multivariable analysis because they might not meet the required event count for multivariable logistic regression analysis.</p><p>As a supplementary analysis, we evaluated the associations between symptoms and each explanatory variable using univariate analysis. The chi-square test was used for categorical variables, and the two-tailed <italic>t</italic> test was used for continuous variables assuming a normal distribution. All analyses were conducted using the same cohort of participants (N=546), and separate multiple regression models were constructed for each constipation-related symptom. No a priori sample size calculation was performed, and all available data were included. A post hoc assessment using G*Power version 3.1.9.7 (Heinrich-Heine-Universit&#x00E4;t D&#x00FC;sseldorf) indicated that the sample size was sufficient for the planned analyses.</p></sec><sec id="s2-4"><title>Ethical Considerations</title><p>This study was conducted in compliance with the World Medical Association Declaration of Helsinki and was approved by the Ethics Committee of Hokkaido University of Science (approval number 24&#x2010;06). All participants voluntarily and anonymously completed the survey and were informed in advance that the submission of their responses would be considered consent to participate. Participants received written explanations prior to participation, and consent was confirmed by submitting responses to the online survey. All data were collected anonymously through an online survey, and no personally identifiable information was obtained. Appropriate measures were taken to ensure data privacy and confidentiality throughout the study. Participants received compensation through the survey panel provider in accordance with its standard incentive policy.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Participants</title><p>Of the 824 panel members invited to participate in the survey, 554 responded. After excluding 8 cases in which the type of laxative could not be identified, 546 subjects were analyzed. The mean age of participants was 69.4 (SD 2.9) years, and 66.8% (365/546) were men. The prescribing department for laxatives was gastroenterology/coloproctology in 24.5% (134/546) of cases. Side effects of laxatives were experienced by 22.2% (121/546) of patients, and hard stools were reported by 23.1% (126/546) of patients. Among the participants, 41.4% (226/546) had less than 3 spontaneous bowel movements per week, 60.4% (330/546) experienced straining during bowel movements, 63.0% (344/546) experienced a sensation of incomplete evacuation, and 44.3% (242/546) reported a sensation of anorectal obstruction or blockage. In total, 6.4% (35/546) of patients required maneuvers to facilitate their bowel movements. Detailed background information on the participants is provided in <xref ref-type="table" rid="table2">Table 2</xref>.</p><table-wrap id="t2" position="float"><label>Table 2.</label><caption><p>Patient characteristics (N=546).</p></caption><table id="table2" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Characteristics</td><td align="left" valign="bottom">Participants</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="2">Outcome variables, n (%)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Frequency of spontaneous bowel movements</td><td align="left" valign="top">226 (41.4)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Straining during bowel movements</td><td align="left" valign="top">330 (60.4)</td></tr><tr><td align="left" valign="top">&#x2003;Sensation of incomplete evacuation</td><td align="left" valign="top">344 (63.0)</td></tr><tr><td align="left" valign="top">&#x2003;Sensation of anorectal obstruction or blockage</td><td align="left" valign="top">242 (44.3)</td></tr><tr><td align="left" valign="top">&#x2003;Manual maneuvers to facilitate defecation</td><td align="left" valign="top">35 (6.4)</td></tr><tr><td align="left" valign="top" colspan="2">Demographic factors</td></tr><tr><td align="left" valign="top">&#x2003;Age (y), mean (SD)</td><td align="left" valign="top">69.4 (2.9)</td></tr><tr><td align="left" valign="top">&#x2003;Male sex, n (%)</td><td align="left" valign="top">365 (66.8)</td></tr><tr><td align="left" valign="top">&#x2003;Female sex, n (%)</td><td align="left" valign="top">181 (33.2)</td></tr><tr><td align="left" valign="top" colspan="2">Stool factor</td></tr><tr><td align="left" valign="top">&#x2003;Hard stool (BSFS<sup><xref ref-type="table-fn" rid="table2fn1">a</xref></sup> type 1&#x2010;2), n (%)</td><td align="left" valign="top">126 (23.1)</td></tr><tr><td align="left" valign="top" colspan="2">Medical factors, n (%)</td></tr><tr><td align="left" valign="top">&#x2003;Gastroenterology/coloproctology</td><td align="left" valign="top">134 (24.5)</td></tr><tr><td align="left" valign="top"><named-content content-type="indent">&#x00A0;&#x00A0;&#x00A0;&#x00A0;</named-content>Experience of adverse effects from constipation medications</td><td align="left" valign="top">121 (22.2)</td></tr><tr><td align="left" valign="top">Medication use, n (%)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">&#x2003;Osmotic laxatives (a salt laxative)</td><td align="left" valign="top">390 (71.4)</td></tr><tr><td align="left" valign="top">&#x2003;Stimulant laxatives</td><td align="left" valign="top">166 (30.4)</td></tr><tr><td align="left" valign="top">&#x2003;Gastric acid&#x2013;suppressing agents</td><td align="left" valign="top">168 (30.8)</td></tr><tr><td align="left" valign="top" colspan="2">Treatment process factors (Likert scale, 1&#x2010;7), mean (SD)</td></tr><tr><td align="left" valign="top">&#x2003;Shared treatment goals</td><td align="left" valign="top">5.37 (1.25)</td></tr><tr><td align="left" valign="top">&#x2003;Adherence to prescribed dosage</td><td align="left" valign="top">5.94 (1.67)</td></tr><tr><td align="left" valign="top" colspan="2">Lifestyle factors (Likert scale, 1&#x2010;7), mean (SD)</td></tr><tr><td align="left" valign="top">&#x2003;Probiotic intake</td><td align="left" valign="top">4.75 (1.77)</td></tr><tr><td align="left" valign="top">&#x2003;Physical activity</td><td align="left" valign="top">3.94 (1.77)</td></tr><tr><td align="left" valign="top">&#x2003;Dietary fiber intake</td><td align="left" valign="top">4.71 (1.20)</td></tr><tr><td align="left" valign="top">&#x2003;Fluid intake</td><td align="left" valign="top">4.39 (1.51)</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><p><sup>a</sup>BSFS: Bristol Stool Form Scale.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Univariate Analysis</title><p>In the univariate analysis, the group with less than 3 spontaneous bowel movements per week showed significantly higher proportions of women, those with adverse effects and hard stools, as well as significantly lower levels of physical activity, dietary fiber intake, and daily fluid intake. Straining during bowel movements was significantly more common in the hard-stool group and was significantly associated with lower levels of shared treatment goals and daily fluid intake. The sensation of incomplete evacuation was more common among those who experienced adverse effects in the hard-stool group and among stimulant laxative users. The sensation of anorectal obstruction or blockage was significantly more frequent in the hard-stool group, among those who experienced adverse effects, and in the group with low adherence to the prescribed dose (Tables S2A-S2E in <xref ref-type="supplementary-material" rid="app1">Multimedia Appendix 1</xref>).</p></sec><sec id="s3-3"><title>Multivariable Logistic Regression Analysis</title><p>Multivariable analysis revealed that each constipation-related symptom had a distinct set of factors that remained significantly associated after adjustment for other variables (<xref ref-type="table" rid="table3">Tables 3</xref><xref ref-type="table" rid="table4"/><xref ref-type="table" rid="table5"/>-<xref ref-type="table" rid="table6">6</xref>).</p><table-wrap id="t3" position="float"><label>Table 3.</label><caption><p>Binary logistic regression analysis of factors associated with having less than 3 spontaneous bowel movements per week<sup><xref ref-type="table-fn" rid="table3fn1">a</xref></sup>.</p></caption><table id="table3" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Explanatory variables</td><td align="left" valign="bottom">OR<sup><xref ref-type="table-fn" rid="table3fn2">b</xref></sup> (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value (adjusted for covariates)</td><td align="left" valign="bottom"><italic>q</italic> value<sup><xref ref-type="table-fn" rid="table3fn3">c</xref></sup> (FDR<sup><xref ref-type="table-fn" rid="table3fn4">d</xref></sup>-adjusted)</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="4">Demographic factor</td></tr><tr><td align="left" valign="top">&#x2003;Sex (female vs male [reference])</td><td align="left" valign="top">1.88 (1.27&#x2010;2.78)</td><td align="left" valign="top">.002</td><td align="left" valign="top">.004</td></tr><tr><td align="left" valign="top" colspan="4">Stool-related factor</td></tr><tr><td align="left" valign="top">&#x2003;Hard stool (BSFS<sup><xref ref-type="table-fn" rid="table3fn5">e</xref></sup> type 1&#x2010;2)</td><td align="left" valign="top">2.15 (1.40&#x2010;3.30)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">.001</td></tr><tr><td align="left" valign="top" colspan="4">Medical factor</td></tr><tr><td align="left" valign="top">&#x2003;Specialty of prescribing physician (gastroenterology or coloproctology vs others [reference])</td><td align="left" valign="top">1.14 (0.75&#x2010;1.75)</td><td align="left" valign="top">.53</td><td align="left" valign="top">.83</td></tr><tr><td align="left" valign="top">&#x2003;Experience of adverse effects from constipation medications (yes vs no [reference])</td><td align="left" valign="top">2.00 (1.30&#x2010;3.07)</td><td align="left" valign="top">.002</td><td align="left" valign="top">.008</td></tr><tr><td align="left" valign="top" colspan="4">Medication use</td></tr><tr><td align="left" valign="top">&#x2003;Osmotic laxatives (yes vs no [reference])</td><td align="left" valign="top">0.71 (0.44&#x2010;1.14)</td><td align="left" valign="top">.15</td><td align="left" valign="top">.28</td></tr><tr><td align="left" valign="top">&#x2003;Stimulant laxatives (yes vs no [reference])</td><td align="left" valign="top">0.99 (0.62&#x2010;1.59)</td><td align="left" valign="top">.96</td><td align="left" valign="top">.96</td></tr><tr><td align="left" valign="top">&#x2003;Gastric acid&#x2013;suppressing agents (yes vs no [reference])</td><td align="left" valign="top">1.07 (0.72&#x2010;1.59)</td><td align="left" valign="top">.74</td><td align="left" valign="top">.74</td></tr><tr><td align="left" valign="top" colspan="4">Treatment process factor</td></tr><tr><td align="left" valign="top">&#x2003;Shared treatment goals</td><td align="left" valign="top">0.96 (0.83&#x2010;1.11)</td><td align="left" valign="top">.57</td><td align="left" valign="top">.57</td></tr><tr><td align="left" valign="top">&#x2003;Adherence to prescribed dosage</td><td align="left" valign="top">0.96 (0.86&#x2010;1.08)</td><td align="left" valign="top">.51</td><td align="left" valign="top">.58</td></tr><tr><td align="left" valign="top" colspan="4">Lifestyle factor</td></tr><tr><td align="left" valign="top">&#x2003;Probiotic intake</td><td align="left" valign="top">1.00 (0.90&#x2010;1.12)</td><td align="left" valign="top">.99</td><td align="left" valign="top">.99</td></tr><tr><td align="left" valign="top">&#x2003;Physical activity</td><td align="left" valign="top">0.86 (0.77&#x2010;0.96)</td><td align="left" valign="top">.007</td><td align="left" valign="top">.04</td></tr><tr><td align="left" valign="top">&#x2003;Dietary fiber intake</td><td align="left" valign="top">0.93 (0.79&#x2010;1.11)</td><td align="left" valign="top">.43</td><td align="left" valign="top">.86</td></tr><tr><td align="left" valign="top">&#x2003;Daily fluid intake</td><td align="left" valign="top">0.92 (0.81&#x2010;1.04)</td><td align="left" valign="top">.20</td><td align="left" valign="top">.27</td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><p><sup>a</sup>All explanatory variables were entered simultaneously into the multivariable logistic regression model, regardless of univariable significance. Area under the receiver operating characteristic curve: 0.685 (95% CI 0.640&#x2010;0.731). Hosmer-Lemeshow test: <italic>P</italic>=.38. </p></fn><fn id="table3fn2"><p><sup>b</sup>OR: odds ratio.</p></fn><fn id="table3fn3"><p><sup>c</sup><italic>q</italic> values were calculated using the Benjamini-Hochberg method to control the false discovery rate (FDR) at &#x003C;.05 across 4 independent models.</p></fn><fn id="table3fn4"><p><sup>d</sup>FDR: false discovery rate.</p></fn><fn id="table3fn5"><p><sup>e</sup>BSFS: Bristol Stool Form Scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" position="float"><label>Table 4.</label><caption><p>Binary logistic regression analysis of factors associated with straining during bowel movements<sup><xref ref-type="table-fn" rid="table4fn1">a</xref></sup>.</p></caption><table id="table4" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Explanatory variables</td><td align="left" valign="bottom">OR<sup><xref ref-type="table-fn" rid="table4fn2">b</xref></sup> (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value (adjusted for covariates)</td><td align="left" valign="bottom"><italic>q</italic> value<sup><xref ref-type="table-fn" rid="table4fn3">c</xref></sup> (FDR<sup><xref ref-type="table-fn" rid="table4fn4">d</xref></sup>-adjusted)</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="4">Demographic factor</td></tr><tr><td align="left" valign="top">&#x2003;Sex (female vs male [reference])</td><td align="left" valign="top">0.52 (0.34&#x2010;0.77)</td><td align="left" valign="top">.001</td><td align="left" valign="top">.004</td></tr><tr><td align="left" valign="top" colspan="4">Stool-related factor</td></tr><tr><td align="left" valign="top">&#x2003;Hard stool (BSFS<sup><xref ref-type="table-fn" rid="table4fn5">e</xref></sup> type 1&#x2010;2)</td><td align="left" valign="top">4.66 (2.74&#x2010;7.92)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">.001</td></tr><tr><td align="left" valign="top" colspan="4">Medical factor</td></tr><tr><td align="left" valign="top">&#x2003;Specialty of prescribing physician (gastroenterology or coloproctology vs others [reference])</td><td align="left" valign="top">1.21 (0.78&#x2010;1.88)</td><td align="left" valign="top">.39</td><td align="left" valign="top">.83</td></tr><tr><td align="left" valign="top">&#x2003;Experience of adverse effects from constipation medications (yes vs no [reference])</td><td align="left" valign="top">1.49 (0.94&#x2010;2.35)</td><td align="left" valign="top">.09</td><td align="left" valign="top">.09</td></tr><tr><td align="left" valign="top" colspan="4">Medication use</td></tr><tr><td align="left" valign="top">&#x2003;Osmotic laxatives (yes vs no [reference])</td><td align="left" valign="top">1.24 (0.75&#x2010;2.03)</td><td align="left" valign="top">.40</td><td align="left" valign="top">.40</td></tr><tr><td align="left" valign="top">&#x2003;Stimulant laxatives (yes vs no [reference])</td><td align="left" valign="top">1.49 (0.91&#x2010;2.45)</td><td align="left" valign="top">.11</td><td align="left" valign="top">.15</td></tr><tr><td align="left" valign="top">&#x2003;Gastric acid&#x2013;suppressing agents (yes vs no [reference])</td><td align="left" valign="top">0.92 (0.62&#x2010;1.38)</td><td align="left" valign="top">.69</td><td align="left" valign="top">.74</td></tr><tr><td align="left" valign="top" colspan="4">Treatment process factor</td></tr><tr><td align="left" valign="top">&#x2003;Shared treatment goals</td><td align="left" valign="top">0.87 (0.74&#x2010;1.02)</td><td align="left" valign="top">.09</td><td align="left" valign="top">.18</td></tr><tr><td align="left" valign="top">&#x2003;Adherence to prescribed dosage</td><td align="left" valign="top">0.95 (0.84&#x2010;1.06)</td><td align="left" valign="top">.34</td><td align="left" valign="top">.68</td></tr><tr><td align="left" valign="top" colspan="4">Lifestyle factor</td></tr><tr><td align="left" valign="top">&#x2003;Probiotic intake</td><td align="left" valign="top">1.04 (0.94&#x2010;1.17)</td><td align="left" valign="top">.45</td><td align="left" valign="top">.99</td></tr><tr><td align="left" valign="top">&#x2003;Physical activity</td><td align="left" valign="top">0.92 (0.82&#x2010;1.03)</td><td align="left" valign="top">.15</td><td align="left" valign="top">.30</td></tr><tr><td align="left" valign="top">&#x2003;Dietary fiber intake</td><td align="left" valign="top">1.04 (0.87&#x2010;1.24)</td><td align="left" valign="top">.68</td><td align="left" valign="top">.88</td></tr><tr><td align="left" valign="top">&#x2003;Daily fluid intake</td><td align="left" valign="top">0.88 (0.77&#x2010;1.00)</td><td align="left" valign="top">.047</td><td align="left" valign="top">.19</td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><p><sup>a</sup>All explanatory variables were entered simultaneously into the multivariable logistic regression model, regardless of univariable significance. Area under the receiver operating characteristic curve 0.708 (95% CI 0.664&#x2010;0.752). Hosmer-Lemeshow test: <italic>P</italic>=.02.</p></fn><fn id="table4fn2"><p><sup>b</sup>OR: odds ratio.</p></fn><fn id="table4fn3"><p><sup>c</sup><italic>q</italic> values were calculated using the Benjamini-Hochberg method to control the false discovery rate (FDR) at &#x003C;.05 across 4 independent models. </p></fn><fn id="table4fn4"><p><sup>d</sup>FDR: false discovery rate.</p></fn><fn id="table4fn5"><p><sup>e</sup>BSFS: Bristol Stool Form Scale. </p></fn></table-wrap-foot></table-wrap><table-wrap id="t5" position="float"><label>Table 5.</label><caption><p>Binary logistic regression analysis of factors associated with the sensation of incomplete evacuation<sup><xref ref-type="table-fn" rid="table5fn1">a</xref></sup>.</p></caption><table id="table5" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Explanatory variables</td><td align="left" valign="bottom">OR<sup><xref ref-type="table-fn" rid="table5fn2">b</xref></sup> (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value (adjusted for covariates)</td><td align="left" valign="bottom"><italic>q</italic> value<sup><xref ref-type="table-fn" rid="table5fn3">c</xref></sup> (FDR<sup><xref ref-type="table-fn" rid="table5fn4">d</xref></sup> -adjusted)</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="4">Demographic factor</td></tr><tr><td align="left" valign="top">&#x2003;Sex (female vs male [reference])</td><td align="left" valign="top">0.98 (0.66&#x2010;1.45)</td><td align="left" valign="top">.91</td><td align="left" valign="top">.91</td></tr><tr><td align="left" valign="top" colspan="4">Stool-related factor</td></tr><tr><td align="left" valign="top">&#x2003;Hard stool (BSFS<sup><xref ref-type="table-fn" rid="table5fn5">e</xref></sup> type 1&#x2010;2)</td><td align="left" valign="top">1.86 (1.18&#x2010;2.92)</td><td align="left" valign="top">.008</td><td align="left" valign="top">.008</td></tr><tr><td align="left" valign="top" colspan="4">Medical factor</td></tr><tr><td align="left" valign="top">&#x2003;Specialty of prescribing physician (gastroenterology or coloproctology vs others [reference])</td><td align="left" valign="top">1.08 (0.71&#x2010;1.65)</td><td align="left" valign="top">.72</td><td align="left" valign="top">.83</td></tr><tr><td align="left" valign="top">&#x2003;Experience of adverse effects from constipation medications (yes vs no [reference])</td><td align="left" valign="top">1.56 (0.99&#x2010;2.46)</td><td align="left" valign="top">.05</td><td align="left" valign="top">.07</td></tr><tr><td align="left" valign="top" colspan="4">Medication use</td></tr><tr><td align="left" valign="top">&#x2003;Osmotic laxatives (yes vs no [reference])</td><td align="left" valign="top">1.36 (0.84&#x2010;2.22)</td><td align="left" valign="top">.21</td><td align="left" valign="top">.28</td></tr><tr><td align="left" valign="top">&#x2003;Stimulant laxatives (yes vs no [reference])</td><td align="left" valign="top">2.01 (1.22&#x2010;3.31)</td><td align="left" valign="top">.006</td><td align="left" valign="top">.02</td></tr><tr><td align="left" valign="top">&#x2003;Gastric acid&#x2013;suppressing agents (yes vs no [reference])</td><td align="left" valign="top">1.22 (0.82&#x2010;1.82)</td><td align="left" valign="top">.32</td><td align="left" valign="top">.74</td></tr><tr><td align="left" valign="top" colspan="4">Treatment process factor</td></tr><tr><td align="left" valign="top">&#x2003;Shared treatment goals</td><td align="left" valign="top">0.85 (0.73&#x2010;0.99)</td><td align="left" valign="top">.04</td><td align="left" valign="top">.16</td></tr><tr><td align="left" valign="top">&#x2003;Adherence to prescribed dosage</td><td align="left" valign="top">0.98 (0.88&#x2010;1.10)</td><td align="left" valign="top">.78</td><td align="left" valign="top">.78</td></tr><tr><td align="left" valign="top" colspan="4">Lifestyle factor</td></tr><tr><td align="left" valign="top">&#x2003;Probiotic intake</td><td align="left" valign="top">1.01 (0.91&#x2010;1.13)</td><td align="left" valign="top">.79</td><td align="left" valign="top">.99</td></tr><tr><td align="left" valign="top">&#x2003;Physical activity</td><td align="left" valign="top">0.99 (0.88&#x2010;1.11)</td><td align="left" valign="top">.84</td><td align="left" valign="top">.84</td></tr><tr><td align="left" valign="top">&#x2003;Dietary fiber intake</td><td align="left" valign="top">0.99 (0.83&#x2010;1.17)</td><td align="left" valign="top">.88</td><td align="left" valign="top">.88</td></tr><tr><td align="left" valign="top">&#x2003;Daily fluid intake</td><td align="left" valign="top">0.90 (0.80&#x2010;1.03)</td><td align="left" valign="top">.12</td><td align="left" valign="top">.24</td></tr></tbody></table><table-wrap-foot><fn id="table5fn1"><p><sup>a</sup>All explanatory variables were entered simultaneously into the multivariable logistic regression model, regardless of univariable significance. Area under the receiver operating characteristic curve 0.647 (95% CI 0.600&#x2010;0.695). Hosmer-Lemeshow test: <italic>P</italic>=.85.</p></fn><fn id="table5fn2"><p><sup>b</sup>OR: odds ratio.</p></fn><fn id="table5fn3"><p><sup>c</sup><italic>q</italic> values were calculated using the Benjamini-Hochberg method to control the false discovery rate (FDR) at &#x003C;.05 across 4 independent models.</p></fn><fn id="table5fn4"><p><sup>d</sup>FDR: false discovery rate.</p></fn><fn id="table5fn5"><p><sup>e</sup>BSFS: Bristol Stool Form Scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6" position="float"><label>Table 6.</label><caption><p>Binary logistic regression analysis of factors associated with the sensation of anorectal obstruction or blockage<sup><xref ref-type="table-fn" rid="table6fn1">a</xref></sup>.</p></caption><table id="table6" frame="hsides" rules="groups"><thead><tr><td align="left" valign="bottom">Explanatory variables</td><td align="left" valign="bottom">OR<sup><xref ref-type="table-fn" rid="table6fn2">b</xref></sup> (95% CI)</td><td align="left" valign="bottom"><italic>P</italic> value (adjusted for covariates)</td><td align="left" valign="bottom"><italic>q</italic> value<sup><xref ref-type="table-fn" rid="table6fn3">c</xref></sup> (FDR<sup><xref ref-type="table-fn" rid="table6fn4">d</xref></sup>-adjusted)</td></tr></thead><tbody><tr><td align="left" valign="top" colspan="4">Demographic factor</td></tr><tr><td align="left" valign="top">&#x2003;Sex (female vs male [reference])</td><td align="left" valign="top">0.66 (0.44&#x2010;0.98)</td><td align="left" valign="top">.04</td><td align="left" valign="top">.053</td></tr><tr><td align="left" valign="top" colspan="4">Stool-related factor</td></tr><tr><td align="left" valign="top">&#x2003;Hard stool (BSFS<sup><xref ref-type="table-fn" rid="table6fn5">e</xref></sup> type 1&#x2010;2)</td><td align="left" valign="top">2.73 (1.78&#x2010;4.20)</td><td align="left" valign="top">&#x003C;.001</td><td align="left" valign="top">.001</td></tr><tr><td align="left" valign="top" colspan="4">Medical factor</td></tr><tr><td align="left" valign="top">&#x2003;Specialty of prescribing physician (gastroenterology or coloproctology vs others [reference])</td><td align="left" valign="top">0.96 (0.63&#x2010;1.46)</td><td align="left" valign="top">.83</td><td align="left" valign="top">.83</td></tr><tr><td align="left" valign="top">&#x2003;Experience of adverse effects from constipation medications (yes vs no [reference])</td><td align="left" valign="top">1.69 (1.10&#x2010;2.59)</td><td align="left" valign="top">.02</td><td align="left" valign="top">.04</td></tr><tr><td align="left" valign="top" colspan="4">Medication use</td></tr><tr><td align="left" valign="top">&#x2003;Osmotic laxatives (yes vs no [reference])</td><td align="left" valign="top">1.59 (0.98&#x2010;2.57)</td><td align="left" valign="top">.06</td><td align="left" valign="top">.24</td></tr><tr><td align="left" valign="top">&#x2003;Stimulant laxatives (yes vs no [reference])</td><td align="left" valign="top">1.52 (0.94&#x2010;2.46)</td><td align="left" valign="top">.09</td><td align="left" valign="top">.15</td></tr><tr><td align="left" valign="top">&#x2003;Gastric acid&#x2013;suppressing agents (yes vs no [reference])</td><td align="left" valign="top">1.19 (0.80&#x2010;1.76)</td><td align="left" valign="top">.39</td><td align="left" valign="top">.74</td></tr><tr><td align="left" valign="top" colspan="4">Treatment process factor</td></tr><tr><td align="left" valign="top">&#x2003;Shared treatment goals</td><td align="left" valign="top">0.91 (0.78&#x2010;1.05)</td><td align="left" valign="top">.19</td><td align="left" valign="top">.25</td></tr><tr><td align="left" valign="top">&#x2003;Adherence to prescribed dosage</td><td align="left" valign="top">0.87 (0.78&#x2010;0.97)</td><td align="left" valign="top">.01</td><td align="left" valign="top">.04</td></tr><tr><td align="left" valign="top" colspan="4">Lifestyle factor</td></tr><tr><td align="left" valign="top">&#x2003;Probiotic intake</td><td align="left" valign="top">1.02 (0.92&#x2010;1.14)</td><td align="left" valign="top">.70</td><td align="left" valign="top">.99</td></tr><tr><td align="left" valign="top">&#x2003;Physical activity</td><td align="left" valign="top">0.96 (0.86&#x2010;1.07)</td><td align="left" valign="top">.42</td><td align="left" valign="top">.56</td></tr><tr><td align="left" valign="top">&#x2003;Dietary fiber intake</td><td align="left" valign="top">0.89 (0.75&#x2010;1.06)</td><td align="left" valign="top">.19</td><td align="left" valign="top">.76</td></tr><tr><td align="left" valign="top">&#x2003;Daily fluid intake</td><td align="left" valign="top">1.01 (0.89&#x2010;1.15)</td><td align="left" valign="top">.87</td><td align="left" valign="top">.87</td></tr></tbody></table><table-wrap-foot><fn id="table6fn1"><p><sup>a</sup>All explanatory variables were entered simultaneously into the multivariable logistic regression model, regardless of univariable significance. Area under the receiver operating characteristic curve 0.682 (95% CI 0.637&#x2010;0.727). Hosmer-Lemeshow test: <italic>P</italic>=.59.</p></fn><fn id="table6fn2"><p><sup>b</sup>OR: odds ratio.</p></fn><fn id="table6fn3"><p><sup>c</sup><italic>q</italic> values were calculated using the Benjamini-Hochberg method to control the false discovery rate (FDR) at &#x003C;.05 across 4 independent models.</p></fn><fn id="table6fn4"><p><sup>d</sup>FDR: false discovery rate.</p></fn><fn id="table6fn5"><p><sup>e</sup>BSFS: Bristol Stool Form Scale. </p></fn></table-wrap-foot></table-wrap><p>Having less than 3 spontaneous bowel movements per week was significantly associated with hard stool (BSFS type 1&#x2010;2; OR 2.15, 95% CI 1.40&#x2010;3.30) and the experience of adverse effects from constipation medications (OR 2.00, 95% CI 1.30&#x2010;3.07). Furthermore, women were significantly associated with the outcome, with higher odds than men (OR 1.88, 95% CI 1.27&#x2010;2.78). In contrast, higher levels of physical activity were significantly associated with a lower likelihood of having less than 3 spontaneous bowel movements per week (OR 0.86, 95% CI 0.77&#x2010;0.96) and were identified as an independent factor associated with less than 3 spontaneous bowel movements per week.</p><p>Straining during bowel movements was most strongly associated with hard stool (OR 4.66, 95% CI 2.74&#x2010;7.92), whereas female sex was associated with lower odds of straining (OR 0.52, 95% CI 0.34&#x2010;0.77). Higher daily fluid intake was also associated with lower odds of straining during bowel movements in the multivariable-adjusted model (OR 0.88, 95% CI 0.77&#x2010;1.00); however, this association did not remain significant after FDR adjustment (<italic>q</italic>=.19). The experience of adverse effects from constipation medications was not statistically significantly associated with straining during bowel movements, although the point estimate suggested a possible positive association (OR 1.49, 95% CI 0.94&#x2010;2.35; <italic>q</italic>=.09).</p><p>Regarding the sensation of incomplete evacuation, hard stool (OR 1.86, 95% CI 1.18&#x2010;2.92) and stimulant laxative use (OR 2.01, 95% CI 1.22&#x2010;3.31) were significantly associated with higher odds of incomplete evacuation. In contrast, greater shared treatment goals were associated with lower odds (OR 0.85, 95% CI 0.73&#x2010;0.99), although this association did not remain significant after FDR adjustment (<italic>q</italic>=.16). The experience of adverse effects was not statistically significantly associated with the sensation of incomplete evacuation, although the point estimate suggested a possible positive association (OR 1.56, 95% CI 0.99&#x2010;2.46; <italic>q</italic>=.07).</p><p>Finally, regarding the sensation of anorectal obstruction or blockage, hard stool (OR 2.73, 95% CI 1.78&#x2010;4.20) and the experience of adverse effects from laxatives (OR 1.69, 95% CI 1.10&#x2010;2.59) were significantly associated factors. In contrast, adherence to the prescribed dosage was significantly and inversely associated with the sensation of anorectal obstruction or blockage (OR 0.87, 95% CI 0.78&#x2010;0.97). While female sex was associated with lower odds than male sex (OR 0.66, 95% CI 0.44&#x2010;0.98), this association, however, did not reach statistical significance after FDR adjustment (<italic>q</italic>=.053).</p><p>Manual maneuvers to facilitate defecation were excluded from the multivariable analysis because of the low number of events.</p><p>All models showed moderate discriminative ability, with AUC values ranging from 0.647 to 0.708. The Hosmer-Lemeshow test indicated no significant lack of fit for the models of low defecation frequency, sensation of incomplete evacuation, and anorectal obstruction. In contrast, the straining model showed a significant result (<italic>P</italic>=.02), with an AUC of 0.708. In a sensitivity analysis using reversed outcome coding, the Hosmer-Lemeshow test for the straining model became nonsignificant (<italic>P</italic>=.17).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><sec id="s4-1"><title>Principal Findings</title><p>This study examined factors associated with individual chronic constipation-related symptoms in adults aged 65 to 74 years with chronic constipation who were receiving pharmacological treatment, using a cross-sectional web-based survey. The findings suggest that these symptoms are not explained by a single underlying factor. Hard stool emerged as a primary factor associated with multiple symptoms, whereas treatment process elements and lifestyle factors contributed to symptom-specific variations. Overall, the clinical interpretation of chronic constipation in this population should take into account both shared and symptom-specific associated factors, rather than relying solely on isolated statistical associations.</p></sec><sec id="s4-2"><title>Significance of Hard Stool as a Common Factor</title><p>Although hard stools are clinically classified as constipation-related symptoms, they were treated in this study as a stool-related characteristic reflecting defecation status. Hard stool (BSFS type 1&#x2010;2) was associated with the frequency of spontaneous bowel movements and subjective symptoms, such as straining during bowel movements, the sensation of incomplete evacuation, and the sensation of anorectal obstruction or blockage.</p><p>Notably, the strength of these associations differed across symptoms. Hard stool was more strongly associated with straining during bowel movements than with the sensation of incomplete evacuation. This difference may reflect underlying pathophysiological mechanisms. Straining is primarily related to increased resistance during stool expulsion and is therefore highly dependent on stool consistency [<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref>]. Hard stool, reflecting prolonged intestinal transit time [<xref ref-type="bibr" rid="ref2">2</xref>], may increase mechanical resistance during defecation, thereby resulting in a stronger association with straining. In contrast, the sensation of incomplete evacuation is not solely determined by stool characteristics but is also related to rectal sensory function and symptom perception. Previous studies have suggested that this sensation does not always correspond to objective physiological measures, such as colonic transit time or anorectal function [<xref ref-type="bibr" rid="ref25">25</xref>-<xref ref-type="bibr" rid="ref30">30</xref>], which may explain the relatively weaker association observed in this study.</p><p>In older adults, age-related factors such as reduced food intake and polypharmacy have been reported to contribute to stool hardening by prolonging intestinal transit time and altering intestinal motility [<xref ref-type="bibr" rid="ref2">2</xref>]. Hard stool formation may contribute to difficulty in defecation or fecal impaction in the rectum [<xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref11">11</xref>]. These findings support the use of standardized measures, such as the BSFS, to evaluate stool consistency as a clinically relevant therapeutic target.</p></sec><sec id="s4-3"><title>Experience of Adverse Effects as a Common Factor</title><p>Here, adverse effects were associated with the frequency of spontaneous bowel movements and the sensation of anorectal obstruction or blockage. These associations may be clinically meaningful because the frequency of spontaneous bowel movements is susceptible to the effects of drug therapy and is known to fluctuate rapidly due to the discontinuation of medication or self-adjustment [<xref ref-type="bibr" rid="ref31">31</xref>]. Additionally, the sensation of anorectal obstruction or blockage reflects instability during evacuation. If the effects of drug therapy are inconsistent, symptoms may persist [<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref27">27</xref>]. Conversely, the absence of clear associations between adverse effects and straining during bowel movements or the sensation of incomplete evacuation may suggest that these symptoms are influenced more strongly by defecatory mechanisms. These symptoms are primarily attributable to defecatory disorders, such as pelvic floor dysfunction [<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref27">27</xref>], and are therefore more likely to be influenced by the defecatory mechanism itself rather than by the consistency of drug efficacy. This may reflect the inclusion of patients for whom pharmacological treatment alone was insufficient. The relationship between symptoms and adverse effects may be confounded by other treatment process factors, such as daily fluid intake and shared treatment goals, which may independently influence symptoms such as straining and incomplete evacuation.</p></sec><sec id="s4-4"><title>Fewer Than 3 Spontaneous Bowel Movements Per Week and Physical Activity</title><p>Among the lifestyle factors examined, physical activity emerged as a factor associated with spontaneous bowel movement frequency. Constipation characterized by reduced bowel movement frequency primarily involves prolonged colonic transit time and decreased intestinal motility [<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref28">28</xref>]. Previous studies targeting physically inactive middle-aged patients with chronic constipation have suggested that exercise interventions are associated with intestinal motility and colonic transit time. However, consistent results regarding bowel movement frequency have not yet been obtained [<xref ref-type="bibr" rid="ref32">32</xref>].</p><p>The observed association may indicate the clinical relevance of physical activity in relation to bowel movement frequency in older adults. Future research should clarify the role of nonpharmacological therapies through evaluations that consider both physical activity levels and functional capacity.</p></sec><sec id="s4-5"><title>Straining During Bowel Movements and Daily Fluid Intake</title><p>Daily fluid intake was associated with reduced straining during defecation before FDR correction; however, this association was not significant after adjustment for multiple comparisons. Straining during defecation results from increased resistance to stool passage and is known to be strongly influenced by stool consistency [<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref>]. Previous studies have reported that insufficient fluid intake contributes to stool hardening [<xref ref-type="bibr" rid="ref29">29</xref>]. The findings suggest a possible association between daily fluid intake and straining during defecation through its influence on stool consistency. However, this interpretation warrants caution because the association did not remain significant after adjustment for multiple comparisons.</p><p>Although the statistical evidence was limited, the assessment of daily fluid intake may still be clinically useful when evaluating straining during defecation.</p></sec><sec id="s4-6"><title>Sensation of Incomplete Evacuation and Shared Treatment Goals</title><p>Although the observed association should be interpreted cautiously because it did not remain significant after correction for multiple testing, it may still provide insight into how patients perceive constipation-related symptoms. Studies involving patients with severe chronic constipation have reported that subjective symptoms, such as a sense of incomplete evacuation, do not necessarily correspond to objective physiological markers, including colonic transit time and anorectal function [<xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref30">30</xref>]. This discrepancy suggests that subjective symptom perception may be influenced by physiological dysfunction and by patients&#x2019; expectations and their understanding of the treatment. Therefore, while the associations observed in this study are exploratory, sharing treatment goals may be associated with how patients perceive a sense of incomplete evacuation. When evaluating and managing a sense of incomplete evacuation, an assessment framework that incorporates both patient-reported perceptions&#x2014;including their understanding of treatment goals&#x2014;and underlying pathophysiology may be clinically useful.</p></sec><sec id="s4-7"><title>Sensation of Anorectal Obstruction or Blockage and Adherence to Prescribed Dosage</title><p>The observed association between the sensation of anorectal obstruction or blockage and adherence to the prescribed dosage suggests that the stability of drug efficacy may play a role in modulating defecatory symptoms. Anorectal obstruction or blockage is reported to be related to the instability of anorectal function and bowel movements [<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref28">28</xref>]. Adherence to the prescribed dosage may be associated with the stability of drug efficacy, thereby potentially modulating symptoms. However, the experience of adverse effects frequently results in medication discontinuation, which may subsequently disrupt bowel habits and influence symptoms. The observed relationship between adherence to the prescribed regimen and symptoms suggests that consistent medication use may help regulate the defecation process and may therefore be associated with a reduced sensation of anorectal obstruction or blockage. Accordingly, a comprehensive evaluation of this sensation should include the assessment of medication adherence, stool consistency, and patient-reported symptoms.</p></sec><sec id="s4-8"><title>Interpretation of Sex Differences</title><p>The observed sex-specific patterns in symptom presentation suggest potential differences in the relative contributions of colonic transit versus evacuation processes.</p><p>The higher likelihood of reduced bowel movement frequency in women may be related to slower colonic transit. Age-related changes, including degeneration of colonic smooth muscle and increased collagen deposition, have been reported to reduce high-amplitude propagating contractions, which may prolong colonic transit time [<xref ref-type="bibr" rid="ref8">8</xref>]. Such mechanisms may contribute to the higher prevalence of reduced bowel movement frequency in older women.</p><p>In contrast, the lower likelihood of straining and anorectal obstruction or blockage in women suggests that men may be more likely to report symptoms related to evacuation difficulty. This pattern may reflect differences in symptom generation and reporting rather than differences in physiological sensitivity alone. While women are generally considered to be at higher risk of structural pelvic floor abnormalities, such as rectocele [<xref ref-type="bibr" rid="ref33">33</xref>], the present findings in a pharmacologically treated population suggest that symptom expression differs, with women more likely to exhibit delayed transit features and men more likely to report outlet-related symptoms.</p></sec><sec id="s4-9"><title>Limitations of the Research and Clinical Significance of This Study</title><p>The findings of this study should be interpreted with caution in light of several limitations. First, due to the cross-sectional design, temporal relationships between the examined factors and constipation symptoms could not be established; therefore, the observed associations should not be interpreted as causal. Second, this study used a web-based survey with participants recruited from an online research panel, which may introduce selection bias. In addition, the study population was restricted to individuals aged 65 to 74 years who were able to complete an online questionnaire. These factors may limit the representativeness of the sample and reduce the generalizability of the findings to older adults (&#x2265;75 y), individuals with cognitive impairment, or those without internet access. Third, key variables&#x2014;including symptoms, lifestyle factors, treatment goal sharing, medication adherence, and adverse effects&#x2014;were assessed using self-reported measures. This may introduce measurement error, recall bias, and reporting bias and could result in residual confounding. Moreover, some survey items were developed based on theoretical considerations and expert review, but lack formal reliability and validity data beyond content validation, and were not fully validated against established instruments or objective indicators. In addition, adverse effects were assessed without detailed information on symptom types or severity. Finally, objective physiological indicators, such as colonic transit time and pelvic floor function, were not evaluated, and these unmeasured factors may have influenced the observed associations. Future studies using longitudinal designs, validated multi-item instruments, and objective clinical measures are warranted to confirm the robustness of these findings.</p><p>Despite these limitations, the clinical significance of this study lies in the use of self-reported patient data. These findings suggest that the symptoms of chronic constipation may involve multifactorial contributors that cannot be explained by a single mechanism. Rather, multiple factors, including defecatory function, lifestyle habits, and treatment-related processes, contribute differentially to each symptom. In the future, symptom-specific assessments using electronic patient-reported outcomes may provide a basis for more targeted and individualized management strategies in older adults.</p></sec><sec id="s4-10"><title>Conclusions</title><p>This study demonstrated that in older adults with chronic constipation, less than 3 spontaneous bowel movements per week, straining during bowel movements, a sensation of incomplete evacuation, and a sensation of anorectal obstruction or blockage were each associated with distinct factors. Hard stool is a key factor common to both objective and subjective symptoms, suggesting the importance of focusing on stool consistency as a central element in evaluating constipation.</p><p>Additionally, although some associations were not significant after correction for multiple comparisons, symptom-specific associations were observed. These findings suggest that uniform, one-size-fits-all approaches to symptom management may be insufficient in older adults with chronic constipation. Instead, symptom management may benefit from a more symptom-oriented approach that considers underlying pathophysiology, lifestyle factors, and treatment processes.</p><p>From a digital health perspective, these results support the use of electronically collected patient-reported outcomes to enable continuous, scalable, and individualized assessment of constipation symptoms. Such approaches may facilitate more targeted and personalized management strategies in real-world clinical settings.</p></sec></sec></body><back><ack><p>The authors would like to express their sincere gratitude to all participants who generously took part in this study. They would also like to thank the 2 pharmacists and the general physician who participated in this study as members of the expert panel. The authors declare the use of generative artificial intelligence (GAI) in the research and writing process. According to the GAIDeT taxonomy (2025), the following tasks were delegated to GAI tools under full human supervision: literature search and systematization, proofreading and editing, and translation. The GAI tool used was PaperPal (Cactus Communications). Responsibility for the final manuscript lies entirely with the authors. GAI tools are not listed as authors and do not bear responsibility for the final outcomes.</p></ack><notes><sec><title>Funding</title><p>The authors declared no financial support was received for this work.</p></sec><sec><title>Data Availability</title><p>The datasets used and analyzed in this study are not publicly available because they contain information that could compromise the privacy of the research participants. However, deidentified datasets are available from the corresponding author upon reasonable requests.</p></sec></notes><fn-group><fn fn-type="con"><p>Conceptualization: MT, TM</p><p>Data curation: MT, TM</p><p>Formal analysis: MT, TM</p><p>Investigation: MT, TM</p><p>Methodology: MT, TM, HS</p><p>Project administration: TM, HS</p><p>Supervision: TM, HS</p><p>Validation: TM, HS</p><p>Writing &#x2013; original draft: MT, TM</p><p>Writing &#x2013; review and editing: MT, TM, HS</p><p>All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.</p></fn><fn fn-type="conflict"><p>None declared.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">AUC</term><def><p>area under the receiver operating characteristic curve</p></def></def-item><def-item><term id="abb2">BSFS</term><def><p>Bristol Stool Form Scale</p></def></def-item><def-item><term id="abb3">FDR</term><def><p>false discovery rate</p></def></def-item><def-item><term id="abb4">OR</term><def><p>odds ratio</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><label>1</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharucha</surname><given-names>AE</given-names> </name><name name-style="western"><surname>Pemberton</surname><given-names>JH</given-names> </name><name name-style="western"><surname>Locke</surname><given-names>GR</given-names>  <suffix>III</suffix></name></person-group><article-title>American Gastroenterological Association technical review on constipation</article-title><source>Gastroenterology</source><year>2013</year><month>01</month><volume>144</volume><issue>1</issue><fpage>218</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.10.028</pub-id><pub-id pub-id-type="medline">23261065</pub-id></nlm-citation></ref><ref id="ref2"><label>2</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallagher</surname><given-names>P</given-names> </name><name name-style="western"><surname>O&#x2019;Mahony</surname><given-names>D</given-names> </name></person-group><article-title>Constipation in old age</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2009</year><volume>23</volume><issue>6</issue><fpage>875</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2009.09.001</pub-id><pub-id pub-id-type="medline">19942165</pub-id></nlm-citation></ref><ref id="ref3"><label>3</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talley</surname><given-names>NJ</given-names> </name><name name-style="western"><surname>Fleming</surname><given-names>KC</given-names> </name><name name-style="western"><surname>Evans</surname><given-names>JM</given-names> </name><etal/></person-group><article-title>Constipation in an elderly community: a study of prevalence and potential risk factors</article-title><source>Am J Gastroenterol</source><year>1996</year><month>01</month><volume>91</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="medline">8561137</pub-id></nlm-citation></ref><ref id="ref4"><label>4</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Giorgio</surname><given-names>R</given-names> </name><name name-style="western"><surname>Ruggeri</surname><given-names>E</given-names> </name><name name-style="western"><surname>Stanghellini</surname><given-names>V</given-names> </name><name name-style="western"><surname>Eusebi</surname><given-names>LH</given-names> </name><name name-style="western"><surname>Bazzoli</surname><given-names>F</given-names> </name><name name-style="western"><surname>Chiarioni</surname><given-names>G</given-names> </name></person-group><article-title>Chronic constipation in the elderly: a primer for the gastroenterologist</article-title><source>BMC Gastroenterol</source><year>2015</year><month>10</month><day>14</day><volume>15</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.1186/s12876-015-0366-3</pub-id><pub-id pub-id-type="medline">26467668</pub-id></nlm-citation></ref><ref id="ref5"><label>5</label><nlm-citation citation-type="web"><article-title>Rome IV</article-title><source>Rome Foundation</source><year>2016</year><access-date>2026-01-14</access-date><comment><ext-link ext-link-type="uri" xlink:href="https://theromefoundation.org/rome-iv/">https://theromefoundation.org/rome-iv/</ext-link></comment></nlm-citation></ref><ref id="ref6"><label>6</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J</given-names> </name><name name-style="western"><surname>To</surname><given-names>WLW</given-names> </name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names> </name><etal/></person-group><article-title>Clinical practice guidelines for the diagnosis of constipation-predominant irritable bowel syndrome and functional constipation in adults: a scoping review</article-title><source>BMC Gastroenterol</source><year>2025</year><month>04</month><day>9</day><volume>25</volume><issue>1</issue><fpage>234</fpage><pub-id pub-id-type="doi">10.1186/s12876-025-03774-6</pub-id><pub-id pub-id-type="medline">40205539</pub-id></nlm-citation></ref><ref id="ref7"><label>7</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>VV</given-names> </name><name name-style="western"><surname>Lau</surname><given-names>NY</given-names> </name><name name-style="western"><surname>Xi</surname><given-names>DJY</given-names> </name><etal/></person-group><article-title>A systematic review of the development and psychometric properties of constipation-related patient-reported outcome measures: opportunities for digital health</article-title><source>J Neurogastroenterol Motil</source><year>2022</year><month>07</month><day>30</day><volume>28</volume><issue>3</issue><fpage>376</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.5056/jnm22004</pub-id><pub-id pub-id-type="medline">35719047</pub-id></nlm-citation></ref><ref id="ref8"><label>8</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mari</surname><given-names>A</given-names> </name><name name-style="western"><surname>Mahamid</surname><given-names>M</given-names> </name><name name-style="western"><surname>Amara</surname><given-names>H</given-names> </name><name name-style="western"><surname>Baker</surname><given-names>FA</given-names> </name><name name-style="western"><surname>Yaccob</surname><given-names>A</given-names> </name></person-group><article-title>Chronic constipation in the elderly patient: updates in evaluation and management</article-title><source>Korean J Fam Med</source><year>2020</year><month>05</month><volume>41</volume><issue>3</issue><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.4082/kjfm.18.0182</pub-id><pub-id pub-id-type="medline">32062960</pub-id></nlm-citation></ref><ref id="ref9"><label>9</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>S</given-names> </name><name name-style="western"><surname>Ohashi</surname><given-names>W</given-names> </name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names> </name><etal/></person-group><article-title>Background factors involved in the epidemiology of functional constipation in the Japanese population: a cross-sectional study</article-title><source>Biopsychosoc Med</source><year>2022</year><month>03</month><day>10</day><volume>16</volume><issue>1</issue><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s13030-022-00237-2</pub-id><pub-id pub-id-type="medline">35272692</pub-id></nlm-citation></ref><ref id="ref10"><label>10</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>CJ</given-names> </name><name name-style="western"><surname>Ford</surname><given-names>AC</given-names> </name></person-group><article-title>Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management</article-title><source>Med J Aust</source><year>2018</year><month>07</month><day>16</day><volume>209</volume><issue>2</issue><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.5694/mja18.00241</pub-id><pub-id pub-id-type="medline">29996755</pub-id></nlm-citation></ref><ref id="ref11"><label>11</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mearin</surname><given-names>F</given-names> </name><name name-style="western"><surname>Lacy</surname><given-names>BE</given-names> </name><name name-style="western"><surname>Chang</surname><given-names>L</given-names> </name><etal/></person-group><article-title>Bowel disorders</article-title><source>Gastroenterology</source><year>2016</year><month>02</month><day>18</day><volume>150</volume><issue>6</issue><fpage>1393</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.02.031</pub-id><pub-id pub-id-type="medline">27144627</pub-id></nlm-citation></ref><ref id="ref12"><label>12</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>SJ</given-names> </name><name name-style="western"><surname>Heaton</surname><given-names>KW</given-names> </name></person-group><article-title>Stool Form Scale as a useful guide to intestinal transit time</article-title><source>Scand J Gastroenterol</source><year>1997</year><month>09</month><volume>32</volume><issue>9</issue><fpage>920</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.3109/00365529709011203</pub-id><pub-id pub-id-type="medline">9299672</pub-id></nlm-citation></ref><ref id="ref13"><label>13</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imhann</surname><given-names>F</given-names> </name><name name-style="western"><surname>Bonder</surname><given-names>MJ</given-names> </name><name name-style="western"><surname>Vich Vila</surname><given-names>A</given-names> </name><etal/></person-group><article-title>Proton pump inhibitors affect the gut microbiome</article-title><source>Gut</source><year>2016</year><month>05</month><volume>65</volume><issue>5</issue><fpage>740</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310376</pub-id><pub-id pub-id-type="medline">26657899</pub-id></nlm-citation></ref><ref id="ref14"><label>14</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>MA</given-names> </name><name name-style="western"><surname>Goodrich</surname><given-names>JK</given-names> </name><name name-style="western"><surname>Maxan</surname><given-names>ME</given-names> </name><etal/></person-group><article-title>Proton pump inhibitors alter the composition of the gut microbiota</article-title><source>Gut</source><year>2016</year><month>05</month><volume>65</volume><issue>5</issue><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310861</pub-id><pub-id pub-id-type="medline">26719299</pub-id></nlm-citation></ref><ref id="ref15"><label>15</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardo</surname><given-names>L</given-names> </name><name name-style="western"><surname>Foti</surname><given-names>M</given-names> </name><name name-style="western"><surname>Ruggia</surname><given-names>O</given-names> </name><name name-style="western"><surname>Chiecchio</surname><given-names>A</given-names> </name></person-group><article-title>Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><month>06</month><volume>8</volume><issue>6</issue><fpage>504</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2009.12.022</pub-id><pub-id pub-id-type="medline">20060064</pub-id></nlm-citation></ref><ref id="ref16"><label>16</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horne</surname><given-names>R</given-names> </name><name name-style="western"><surname>Chapman</surname><given-names>SCE</given-names> </name><name name-style="western"><surname>Parham</surname><given-names>R</given-names> </name><name name-style="western"><surname>Freemantle</surname><given-names>N</given-names> </name><name name-style="western"><surname>Forbes</surname><given-names>A</given-names> </name><name name-style="western"><surname>Cooper</surname><given-names>V</given-names> </name></person-group><article-title>Understanding patients&#x2019; adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework</article-title><source>PLOS One</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e80633</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0080633</pub-id><pub-id pub-id-type="medline">24312488</pub-id></nlm-citation></ref><ref id="ref17"><label>17</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L</given-names> </name><name name-style="western"><surname>Chey</surname><given-names>WD</given-names> </name><name name-style="western"><surname>Imdad</surname><given-names>A</given-names> </name><etal/></person-group><article-title>American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation</article-title><source>Gastroenterology</source><year>2023</year><month>06</month><volume>164</volume><issue>7</issue><fpage>1086</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2023.03.214</pub-id><pub-id pub-id-type="medline">37211380</pub-id></nlm-citation></ref><ref id="ref18"><label>18</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindberg</surname><given-names>G</given-names> </name><name name-style="western"><surname>Hamid</surname><given-names>SS</given-names> </name><name name-style="western"><surname>Malfertheiner</surname><given-names>P</given-names> </name><etal/></person-group><article-title>World Gastroenterology Organisation global guideline: constipation--a global perspective</article-title><source>J Clin Gastroenterol</source><year>2011</year><month>07</month><volume>45</volume><issue>6</issue><fpage>483</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1097/MCG.0b013e31820fb914</pub-id><pub-id pub-id-type="medline">21666546</pub-id></nlm-citation></ref><ref id="ref19"><label>19</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ihara</surname><given-names>E</given-names> </name><name name-style="western"><surname>Manabe</surname><given-names>N</given-names> </name><name name-style="western"><surname>Ohkubo</surname><given-names>H</given-names> </name><etal/></person-group><article-title>Evidence-based clinical guidelines for chronic constipation 2023</article-title><source>Digestion</source><year>2025</year><volume>106</volume><issue>1</issue><fpage>62</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1159/000540912</pub-id><pub-id pub-id-type="medline">39159626</pub-id></nlm-citation></ref><ref id="ref20"><label>20</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>SSC</given-names> </name><name name-style="western"><surname>Rattanakovit</surname><given-names>K</given-names> </name><name name-style="western"><surname>Patcharatrakul</surname><given-names>T</given-names> </name></person-group><article-title>Diagnosis and management of chronic constipation in adults</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2016</year><month>05</month><volume>13</volume><issue>5</issue><fpage>295</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.53</pub-id><pub-id pub-id-type="medline">27033126</pub-id></nlm-citation></ref><ref id="ref21"><label>21</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suares</surname><given-names>NC</given-names> </name><name name-style="western"><surname>Ford</surname><given-names>AC</given-names> </name></person-group><article-title>Systematic review: the effects of fibre in the management of chronic idiopathic constipation</article-title><source>Aliment Pharmacol Ther</source><year>2011</year><month>04</month><volume>33</volume><issue>8</issue><fpage>895</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2011.04602.x</pub-id><pub-id pub-id-type="medline">21332763</pub-id></nlm-citation></ref><ref id="ref22"><label>22</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#x00FC;ller-Lissner</surname><given-names>SA</given-names> </name><name name-style="western"><surname>Kamm</surname><given-names>MA</given-names> </name><name name-style="western"><surname>Scarpignato</surname><given-names>C</given-names> </name><name name-style="western"><surname>Wald</surname><given-names>A</given-names> </name></person-group><article-title>Myths and misconceptions about chronic constipation</article-title><source>Am J Gastroenterol</source><year>2005</year><month>01</month><volume>100</volume><issue>1</issue><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.40885.x</pub-id><pub-id pub-id-type="medline">15654804</pub-id></nlm-citation></ref><ref id="ref23"><label>23</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camilleri</surname><given-names>M</given-names> </name><name name-style="western"><surname>Ford</surname><given-names>AC</given-names> </name><name name-style="western"><surname>Mawe</surname><given-names>GM</given-names> </name><etal/></person-group><article-title>Chronic constipation</article-title><source>Nat Rev Dis Primers</source><year>2017</year><month>12</month><day>14</day><volume>3</volume><fpage>17095</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.95</pub-id><pub-id pub-id-type="medline">29239347</pub-id></nlm-citation></ref><ref id="ref24"><label>24</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verster</surname><given-names>JC</given-names> </name><name name-style="western"><surname>Sandalova</surname><given-names>E</given-names> </name><name name-style="western"><surname>Garssen</surname><given-names>J</given-names> </name><name name-style="western"><surname>Bruce</surname><given-names>G</given-names> </name></person-group><article-title>The use of single-item ratings versus traditional multiple-item questionnaires to assess mood and health</article-title><source>Eur J Investig Health Psychol Educ</source><year>2021</year><month>02</month><day>20</day><volume>11</volume><issue>1</issue><fpage>183</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.3390/ejihpe11010015</pub-id><pub-id pub-id-type="medline">34542458</pub-id></nlm-citation></ref><ref id="ref25"><label>25</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bharucha</surname><given-names>AE</given-names> </name><name name-style="western"><surname>Wald</surname><given-names>A</given-names> </name><name name-style="western"><surname>Enck</surname><given-names>P</given-names> </name><name name-style="western"><surname>Rao</surname><given-names>S</given-names> </name></person-group><article-title>Functional anorectal disorders</article-title><source>Gastroenterology</source><year>2006</year><month>04</month><volume>130</volume><issue>5</issue><fpage>1510</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.11.064</pub-id><pub-id pub-id-type="medline">16678564</pub-id></nlm-citation></ref><ref id="ref26"><label>26</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>SSC</given-names> </name></person-group><article-title>Advances in diagnostic assessment of fecal incontinence and dyssynergic defecation</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><month>11</month><volume>8</volume><issue>11</issue><fpage>910</fpage><lpage>919</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2010.06.004</pub-id><pub-id pub-id-type="medline">20601142</pub-id></nlm-citation></ref><ref id="ref27"><label>27</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>SSC</given-names> </name><name name-style="western"><surname>Patcharatrakul</surname><given-names>T</given-names> </name></person-group><article-title>Diagnosis and treatment of dyssynergic defecation</article-title><source>J Neurogastroenterol Motil</source><year>2016</year><month>07</month><day>30</day><volume>22</volume><issue>3</issue><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.5056/jnm16060</pub-id><pub-id pub-id-type="medline">27270989</pub-id></nlm-citation></ref><ref id="ref28"><label>28</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>SSC</given-names> </name><name name-style="western"><surname>Meduri</surname><given-names>K</given-names> </name></person-group><article-title>What is necessary to diagnose constipation?</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2011</year><month>02</month><volume>25</volume><issue>1</issue><fpage>127</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2010.11.001</pub-id><pub-id pub-id-type="medline">21382584</pub-id></nlm-citation></ref><ref id="ref29"><label>29</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kira</surname><given-names>I</given-names> </name></person-group><article-title>Evidence for the efficacy of fluid intake for constipation as nursing care&#x2015;integrated literature review&#x2015;</article-title><source>Jpn J Nurs Art Sci</source><year>2013</year><volume>12</volume><issue>2</issue><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.18892/jsnas.12.2_33</pub-id></nlm-citation></ref><ref id="ref30"><label>30</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mertz</surname><given-names>H</given-names> </name><name name-style="western"><surname>Naliboff</surname><given-names>B</given-names> </name><name name-style="western"><surname>Mayer</surname><given-names>EA</given-names> </name></person-group><article-title>Symptoms and physiology in severe chronic constipation</article-title><source>Am J Gastroenterol</source><year>1999</year><month>01</month><volume>94</volume><issue>1</issue><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.1999.00783.x</pub-id><pub-id pub-id-type="medline">9934743</pub-id></nlm-citation></ref><ref id="ref31"><label>31</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinson</surname><given-names>J</given-names> </name><name name-style="western"><surname>Achenbach</surname><given-names>H</given-names> </name><name name-style="western"><surname>Terreri</surname><given-names>B</given-names> </name><name name-style="western"><surname>Boules</surname><given-names>M</given-names> </name></person-group><article-title>Effects of treatment cessation and re-treatment in randomized controlled trials of prucalopride in patients with chronic idiopathic constipation</article-title><source>Neurogastroenterol Motil</source><year>2023</year><month>07</month><volume>35</volume><issue>7</issue><fpage>e14563</fpage><pub-id pub-id-type="doi">10.1111/nmo.14563</pub-id><pub-id pub-id-type="medline">37010859</pub-id></nlm-citation></ref><ref id="ref32"><label>32</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Schryver</surname><given-names>AM</given-names> </name><name name-style="western"><surname>Keulemans</surname><given-names>YC</given-names> </name><name name-style="western"><surname>Peters</surname><given-names>HP</given-names> </name><etal/></person-group><article-title>Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation</article-title><source>Scand J Gastroenterol</source><year>2005</year><month>04</month><volume>40</volume><issue>4</issue><fpage>422</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1080/00365520510011641</pub-id><pub-id pub-id-type="medline">16028436</pub-id></nlm-citation></ref><ref id="ref33"><label>33</label><nlm-citation citation-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>JM</given-names> </name><name name-style="western"><surname>Vaughan</surname><given-names>CP</given-names> </name><name name-style="western"><surname>Goode</surname><given-names>PS</given-names> </name><etal/></person-group><article-title>Prevalence and trends of symptomatic pelvic floor disorders in U.S. women</article-title><source>Obstet Gynecol</source><year>2014</year><month>01</month><volume>123</volume><issue>1</issue><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1097/AOG.0000000000000057</pub-id><pub-id pub-id-type="medline">24463674</pub-id></nlm-citation></ref></ref-list><app-group><supplementary-material id="app1"><label>Multimedia Appendix 1</label><p>Questionnaire and supplementary univariable analyses of constipation-related symptoms.</p><media xlink:href="formative_v10i1e93531_app1.xlsx" xlink:title="XLSX File, 33 KB"/></supplementary-material></app-group></back></article>